Details of the Drug

General Information of Drug (ID: DM672AH)

Drug Name
Aspirin
Synonyms
ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [1]
Adenomatous colon polyp N.A. Approved [1]
Back pain ME84.Z Approved [1]
Common cold CA00 Approved [1]
Headache 8A80-8A84 Approved [1]
Migraine disorder N.A. Approved [1]
Myocardial infarction BA41-BA43 Approved [2]
Osteoarthritis FA00-FA05 Approved [1]
Pain MG30-MG3Z Approved [3]
Cardiovascular disease BA00-BE2Z Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [4]
Colon cancer 2B90.Z Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
A01AD05: Aspirin
A01AD: Other agents for local oral treatment
A01A: STOMATOLOGICAL PREPARATIONS
A01: STOMATOLOGICAL PREPARATIONS
A: ALIMENTARY TRACT AND METABOLISM
B01AC06: Aspirin
B01AC: Platelet aggregation inhibitors excl. heparin
B01A: ANTITHROMBOTIC AGENTS
B01: ANTITHROMBOTIC AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
N02BA01: Aspirin
N02BA: Salicylic acid and derivatives
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
N02BA01: Aspirin
N02BA: Salicylic acid and derivatives
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
N02BA01: Aspirin
N02BA: Salicylic acid and derivatives
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 180.16
Logarithm of the Partition Coefficient (xlogp) 1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [6]
Elimination
1.4% of drug is excreted from urine in the unchanged form [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.26 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 370.22296 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.68% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.22 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Acute lymphocytic leukaemia rs10841753 SLCO1B1 OTNEN8QK [8]
Acute lymphocytic leukaemia rs10740455 C10orf11 OTIPNKTU [8]
Adverse drug reaction rs3892097 CYP2D6 OTZJC802 [9]
Adverse reaction rs7715172 EGFLAM OTACZZJ0 [10]
Adverse reaction rs4502542 FHIT OTGWBSLA [10]
Adverse reaction rs3810046 LAMA1 OTQZMP86 [10]
Anaemia rs1127354 ITPA OTQ47WVR [11]
Capillary leak syndrome Not Available ANGPTL4 OTQL5SPX [12]
Completed suicide rs7569963 CREB1 OT1MDLA1 [13]
Diarrhoea rs2231142 ABCG2 OTW8V2V1 [14]
Gastrointestinal tract mucosal discolouration Not Available VIM OTGZLW4J [12]
Haemorrhagic disorder Not Available MPO OTOOXLIN [12]
Inflammations Not Available PTGES3 OTPPQWI0 [12]
Liver injury rs3129900 C6orf10 OT5GE8IO [15]
Liver injury HLA-DRB5*01:01 HLA-DRB5 OTUX5TWM [15]
Liver injury HLA-DQA1*01:02 HLA-DQA1 OTC6GISG [15]
Liver injury HLA-B*18:01 HLA-B OTNXFWY2 [16]
Suicidal ideation rs4825476 GRIA3 OT34CNBR [17]
Suicidal ideation rs2518224 GRIK2 OTQ41U3D [17]
Urticaria HLA-DQB1*06:09 HLA-DQB OTVVI3UI [18]
Urticaria HLA-DPB1*17:01 HLA-DPB OTW8JHU2 [18]
⏷ Show the Full List of 21 ADR Information of This Drug
Chemical Identifiers
Formula
C9H8O4
IUPAC Name
2-acetyloxybenzoic acid
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChIKey
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2244
ChEBI ID
CHEBI:15365
CAS Number
50-78-2
UNII
R16CO5Y76E
DrugBank ID
DB00945
TTD ID
D0GY5Z
VARIDT ID
DR00203
INTEDE ID
DR1749
ACDINA ID
D00046
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]
Prostaglandin G/H synthase (COX) TTK0943 PGH1_HUMAN ; PGH2_HUMAN Inhibitor [19]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Probable small intestine urate exporter (SLC17A4) DTHE530 S17A4_HUMAN Substrate [20]
Sodium-dependent phosphate transport protein 1 (SLC17A1) DT8ARWJ NPT1_HUMAN Substrate [21]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [22]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [23]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [24]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [25]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [26]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [27]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [24]
N-acetyltransferase 2 (NAT2) DER7TA0 ARY2_HUMAN Substrate [24]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein epsilon OT3WQXNA 1433E_HUMAN Gene/Protein Processing [28]
14-3-3 protein theta OTWG7F3H 1433T_HUMAN Gene/Protein Processing [29]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [30]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12) OTWICA51 PSD12_HUMAN Gene/Protein Processing [29]
26S proteasome regulatory subunit 10B (PSMC6) OTG8997V PRS10_HUMAN Gene/Protein Processing [31]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Gene/Protein Processing [32]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Gene/Protein Processing [31]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Protein Interaction/Cellular Processes [33]
85/88 kDa calcium-independent phospholipase A2 (PLA2G6) OT5FL0WU PLPL9_HUMAN Gene/Protein Processing [31]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Gene/Protein Processing [34]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute coronary syndrome
ICD Disease Classification BA41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.29E-14 -7.08E-01 -1.99E+00
Probable small intestine urate exporter (SLC17A4) DTP SLC17A4 1.00E-02 -1.74E-01 -8.13E-01
Sodium-dependent phosphate transport protein 1 (SLC17A1) DTP NPT1 3.04E-01 -5.95E-02 -5.29E-01
Organic anion transporter 2 (SLC22A7) DTP OAT2 8.78E-06 -2.19E-01 -6.62E-01
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 1.61E-12 1.01E+00 1.51E+00
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 2.00E-01 5.79E-02 3.00E-01
N-acetyltransferase 2 (NAT2) DME NAT2 3.49E-01 -8.28E-02 -3.71E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.03E-02 -1.19E-01 -5.11E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.63E-03 -1.18E-01 -3.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SF295 CTRP1 6.9192 8.2887 4.6113 0.439
GaMG CTRP1 7.1536 9.0184 4.4354 0.9858
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-59 CTRP1 6.5126 8.6522 4.2802 2.8178
HEC-265 CTRP1 6.777 7.8394 4.7169 0.1949
HEC-251 CTRP1 7.0489 8.3879 4.6249 0.3262
HEC-6 CTRP1 7.1416 8.4289 4.6445 0.2359
HEC-108 CTRP1 7.1723 8.4808 4.6376 0.2412
KLE CTRP1 7.2272 9.37 4.3315 1.4305
MFE-319 CTRP1 7.5327 12.3411 3.2145 8.3381
Ishikawa (Heraklio) 02 ER- CTRP1 6.5731 7.7153 4.6846 0.3928
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MC116 CTRP1 6.066 7.1269 4.6951 0.8073
BL-70 CTRP1 6.5548 7.5622 4.7324 0.246
HT CTRP1 6.8256 8.249 4.589 0.5861
P3HR-1 CTRP1 7.251 9.2174 4.4007 1.0582
KE-97 CTRP1 7.5566 8.7161 4.6908 0.066
Ku812 CTRP1 7.8131 9.5404 4.5022 0.3329
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CTRP1 7.541 9.4261 4.4407 0.6608
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LS513 CTRP1 5.859 7.7362 4.3138 4.0351
DLD-1 CTRP1 6.1823 7.2337 4.7049 0.6238
COLO205 CTRP1 6.7538 7.9817 4.6582 0.3755
LS411N CTRP1 6.8916 8.2487 4.6151 0.4425
GP2d CTRP1 7.1627 8.617 4.5865 0.3857
SW48 CTRP1 7.1842 9.2005 4.3786 1.2328
SW403 CTRP1 7.2643 9.004 4.486 0.677
SK-CO-1 CTRP1 7.3318 9.0128 4.5092 0.5461
C2BBe1 CTRP1 7.6351 9.4797 4.4577 0.5447
SNU-C2A CTRP1 7.7127 10.8186 3.9749 2.8524
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-6 CTRP1 6.3941 7.1951 4.8016 0.1319
SNU-449 CTRP1 7.6338 9.3862 4.4904 0.4426
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1930 CTRP1 5.3725 7.3091 4.1833 6.6819
BEN CTRP1 6.3464 7.3765 4.7191 0.4165
HCC33 CTRP1 6.4741 8.2803 4.4187 1.9313
COLO 668 CTRP1 6.5127 8.2074 4.4679 1.557
LC-1/sq-SF CTRP1 6.5454 7.9971 4.567 0.9456
NCI-H82 CTRP1 6.6323 9.5221 3.9621 4.9346
LCLC-103H CTRP1 6.6779 8.0017 4.6211 0.5667
DV-90 CTRP1 6.7296 9.1512 4.1801 3.1197
NCI-H522 CTRP1 6.7319 9.225 4.1494 3.3331
NCI-H2126 CTRP1 6.76 8.1646 4.5938 0.6169
NCI-H1573 CTRP1 6.7715 9.1098 4.2198 2.7674
NCI-H1975 CTRP1 6.8144 8.9195 4.3211 2.0301
COR-L279 CTRP1 6.8993 8.4942 4.5275 0.7906
NCI-H810 CTRP1 6.9211 8.6568 4.4748 1.0204
EPLC-272H CTRP1 6.9291 9.2118 4.2563 2.2671
NCI-H1915 CTRP1 6.9753 8.9596 4.3803 1.4591
Lu-65 CTRP1 6.9845 8.5662 4.5355 0.6851
NCI-H1435 CTRP1 7.0179 9.1994 4.304 1.8442
NCI-H2286 CTRP1 7.0371 8.399 4.6166 0.3567
HCC78 CTRP1 7.0398 8.6904 4.5117 0.7418
Calu-3 CTRP1 7.0525 9.1831 4.3266 1.667
NCI-H2029 CTRP1 7.1061 8.8187 4.4909 0.7774
A-549 CTRP1 7.1511 9.5471 4.2258 2.13
LXF 289 CTRP1 7.1514 9.1843 4.3706 1.3089
NCI-H358 CTRP1 7.1687 9.175 4.3818 1.2331
KNS-62 CTRP1 7.2073 8.7367 4.5607 0.4439
NCI-H1568 CTRP1 7.2295 8.9064 4.508 0.6164
SHP-77 CTRP1 7.2298 10.6958 3.7779 5.0064
COR-L88 CTRP1 7.241 8.7168 4.5804 0.3654
EBC-1 CTRP1 7.2633 9.1934 4.415 0.9807
NCI-H1793 CTRP1 7.2666 8.7773 4.5686 0.3881
Lu-99 CTRP1 7.3009 9.0636 4.4786 0.6799
RERF-LC-KJ CTRP1 7.325 8.9075 4.5443 0.4332
VMRC-LCD CTRP1 7.3431 9.0368 4.5049 0.5545
NCI-H650 CTRP1 7.3474 8.9992 4.5201 0.4996
NCI-H727 CTRP1 7.3525 9.2543 4.4289 0.8439
NCI-H2009 CTRP1 7.4041 9.035 4.5288 0.4407
NCI-H23 CTRP1 7.4086 9.3289 4.4239 0.8208
NCI-H661 CTRP1 7.4277 10.3662 4.0227 2.984
ChaGo-K-1 CTRP1 7.488 9.1421 4.5223 0.4186
LCLC-97TM1 CTRP1 7.5366 10.0523 4.2013 1.7741
NCI-H1666 CTRP1 7.5512 15.2934 1.8402 16.879
HARA [Human squamous cell lung carcinoma] CTRP1 7.5557 9.1927 4.5295 0.3665
NCI-H1299 CTRP1 7.5675 10.5307 4.023 2.77
NCI-H1355 CTRP1 7.5718 9.784 4.3204 1.1378
Calu-6 CTRP1 7.5772 9.2834 4.5056 0.4248
DMS 273 CTRP1 7.6173 9.2463 4.5333 0.3308
NCI-H1944 CTRP1 7.679 9.5822 4.4377 0.5866
NCI-H1792 CTRP1 7.7037 9.3886 4.5153 0.3427
NCI-H1048 CTRP1 7.7301 9.4905 4.4894 0.4008
NCI-H2405 CTRP1 7.7533 9.9884 4.3184 0.9922
NCI-H1437 CTRP1 7.9124 9.7788 4.4554 0.4145
HCC44 CTRP1 8.0087 9.6361 4.5386 0.1953
NCI-H1373 CTRP1 8.2113 9.9809 4.4926 0.2273
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-450 CTRP1 6.9792 8.297 4.6311 0.3417
KYSE-410 CTRP1 7.6431 9.6459 4.4007 0.7425
KYSE-140 CTRP1 7.755 9.5838 4.4658 0.457
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COV318 CTRP1 6.6578 7.5754 4.7649 0.1283
OVMANA CTRP1 6.6932 8.088 4.5951 0.6657
HEY A8 CTRP1 7.0215 9.0155 4.3791 1.4105
JHOS-4 CTRP1 7.0468 9.3454 4.2583 2.0796
SK-OV-3 CTRP1 7.5946 8.9798 4.6163 0.1599
EFO-21 CTRP1 7.7465 9.0731 4.6369 0.1
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HPAC CTRP1 6.5619 8.8709 4.2117 3.2154
PaTu 8902 CTRP1 6.7441 8.1905 4.5777 0.7
SUIT-2 CTRP1 6.8747 8.2528 4.607 0.4822
KP-3 CTRP1 6.9066 9.853 3.9702 4.2807
QGP-1 CTRP1 7.1221 8.4677 4.6239 0.296
CFPAC-1 CTRP1 7.239 9.0575 4.4561 0.8192
Panc 03.27 CTRP1 7.4543 8.9374 4.5814 0.2734
HuP-T4 CTRP1 7.5449 9.2375 4.5098 0.428
Capan-2 CTRP1 7.8235 11.9675 3.5455 5.445
Panc 10.05 CTRP1 7.8721 9.6765 4.4764 0.3755
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 CTRP1 7.1558 10.0516 4.0175 3.4719
NCI-H2052 CTRP1 7.2121 9.4294 4.3014 1.6113
MSTO-211H CTRP1 7.3255 9.1947 4.4401 0.818
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 7.5108 8.7532 4.6633 0.105
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-361 CTRP1 6.4087 8.5032 4.289 2.9563
Hs 936.T CTRP1 6.8003 7.9613 4.6829 0.2746
Hs 852.T CTRP1 7.2428 8.7623 4.565 0.4112
Hs 944.T CTRP1 7.3012 8.7768 4.5816 0.3345
COLO 741 CTRP1 7.3019 9.3047 4.389 1.066
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-401 CTRP1 8.6708 18.3103 1.1474 17.4638
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-4 CTRP1 6.615 8.8699 4.2407 2.9058
SH-10-TC CTRP1 7.0526 8.3027 4.656 0.2407
Fu97 CTRP1 7.1173 8.7545 4.5192 0.6515
MKN7 CTRP1 7.1208 9.2838 4.3177 1.6313
MKN74 CTRP1 7.987 9.9812 4.4119 0.5047
SNG-M CTRP1 7.595 9.2741 4.5155 0.388
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 7.3166 8.5612 4.661 0.1489
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 CTRP1 7.2328 9.0232 4.4663 0.7809
UM-UC-3 CTRP1 7.2559 8.853 4.5376 0.4934
HT-1376 CTRP1 7.5926 9.4269 4.4604 0.5598
KMBC-2 CTRP1 7.686 9.4829 4.4757 0.461
RT-4 CTRP1 7.8755 10.5011 4.1753 1.5397

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aspirin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ibuprofen DM8VCBE Major Increased risk of bleeding by the combination of Aspirin and Ibuprofen. Pain [MG30-MG3Z] [35]
Coadministration of a Drug Treating the Disease Different from Aspirin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [36]
Tromethamine DMOBLGK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [36]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Aspirin and Glibenclamide. Acute diabete complication [5A2Y] [37]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-glulisine. Acute diabete complication [5A2Y] [38]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-aspart. Acute diabete complication [5A2Y] [38]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Aspirin and Glipizide. Acute diabete complication [5A2Y] [37]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Budesonide. Asthma [CA23] [39]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Aspirin and Ofloxacin. Bacterial infection [1A00-1C4Z] [40]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Kanamycin. Bacterial infection [1A00-1C4Z] [41]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Aspirin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [40]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Streptomycin. Bacterial infection [1A00-1C4Z] [41]
Gemifloxacin DMHT34O Moderate Additive CNS stimulant effects by the combination of Aspirin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [40]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Aspirin and Norfloxacin. Bacterial infection [1A00-1C4Z] [40]
ABT-492 DMJFD2I Moderate Additive CNS stimulant effects by the combination of Aspirin and ABT-492. Bacterial infection [1A00-1C4Z] [40]
Rabeprazole DMMZXIW Minor Decreased absorption of Aspirin due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [42]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Netilmicin. Bacterial infection [1A00-1C4Z] [41]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Aspirin and Levofloxacin. Bacterial infection [1A00-1C4Z] [43]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Aspirin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [40]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Etidronic acid. Bone paget disease [FB85] [44]
Ketoprofen DMRKXPT Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Ketoprofen. Chronic pain [MG30] [45]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Aspirin and Levomilnacipran. Chronic pain [MG30] [46]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Aspirin and Anisindione. Coagulation defect [3B10] [47]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Aspirin and Regorafenib. Colorectal cancer [2B91] [48]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Aspirin and Drospirenone. Contraceptive management [QA21] [49]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Aspirin and Ardeparin. Coronary thrombosis [BA43] [50]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Aspirin and Danaparoid. Deep vein thrombosis [BD71] [50]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Aspirin and Rivaroxaban. Deep vein thrombosis [BD71] [51]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Aspirin and Sertraline. Depression [6A70-6A7Z] [46]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Aspirin and Vilazodone. Depression [6A70-6A7Z] [46]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Aspirin and Vortioxetine. Depression [6A70-6A7Z] [46]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Aspirin and Milnacipran. Depression [6A70-6A7Z] [46]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Aspirin and Escitalopram. Depression [6A70-6A7Z] [46]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Aspirin and Desvenlafaxine. Depression [6A70-6A7Z] [46]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Aspirin and Clomipramine. Depression [6A70-6A7Z] [46]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Aspirin and Heme. Discovery agent [N.A.] [52]
SODIUM CITRATE DMHPD2Y Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [36]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Aspirin and Apigenin. Discovery agent [N.A.] [53]
Fosphenytoin DMOX3LB Minor Increased plasma concentration of Aspirin and Fosphenytoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [54]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Aspirin due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [42]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Aspirin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [48]
Brinzolamide DMBAPFG Major Increased risk of metabolic acidosis by the combination of Aspirin and Brinzolamide. Glaucoma [9C61] [55]
Dichlorphenamide DMH7IDQ Major Increased risk of metabolic acidosis by the combination of Aspirin and Dichlorphenamide. Glaucoma [9C61] [55]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Aspirin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [56]
Sodium acetate anhydrous DMH21E0 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [36]
Probenecid DMMFWOJ Moderate Antagonize the effect of Aspirin when combined with Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [48]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Aspirin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [57]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Aspirin and Acalabrutinib. Mature B-cell lymphoma [2A85] [58]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Aspirin and Ibrutinib. Mature B-cell lymphoma [2A85] [59]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Aspirin and Ponatinib. Mature B-cell lymphoma [2A85] [58]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Aspirin and Exjade. Mineral absorption/transport disorder [5C64] [60]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Deflazacort. Muscular dystrophy [8C70] [39]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Aspirin and Prasugrel. Myocardial infarction [BA41-BA43] [61]
Metoclopramide DMFA5MY Minor Altered absorption of Aspirin due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [62]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Aspirin and Nepafenac. Osteoarthritis [FA00-FA05] [63]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Aspirin and MK-4827. Ovarian cancer [2C73] [48]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Bromfenac. Postoperative inflammation [1A00-CA43] [45]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Aspirin and Epoprostenol. Pulmonary hypertension [BB01] [64]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Aspirin and Iloprost. Pulmonary hypertension [BB01] [64]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Aspirin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [40]
Oxaprozin DM9UB0P Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Oxaprozin. Rheumatoid arthritis [FA20] [45]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Dexamethasone. Rheumatoid arthritis [FA20] [39]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Aspirin and Leflunomide. Rheumatoid arthritis [FA20] [56]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [39]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Aspirin and Curcumin. Solid tumour/cancer [2A00-2F9Z] [65]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Pitolisant. Somnolence [MG42] [48]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Aspirin and Caplacizumab. Thrombocytopenia [3B64] [62]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Aspirin and Apixaban. Thrombosis [DB61-GB90] [48]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Aspirin and Cabozantinib. Thyroid cancer [2D10] [66]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Aspirin and Tolbutamide. Type 2 diabetes mellitus [5A11] [37]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [38]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin degludec. Type-1/2 diabete [5A10-5A11] [38]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Plazomicin. Urinary tract infection [GC08] [41]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Aspirin and Betrixaban. Venous thromboembolism [BD72] [66]
⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acrylic acid E00132 6581 Other agent
Allura red AC dye E00338 33258 Colorant
Benzoic acid E00009 243 Antimicrobial preservative
Benzosulfimide E00076 5143 Flavoring agent
Butylated hydroxytoluene E00336 31404 Antioxidant
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
Cholesteryl stearate E00398 118246 Emollient; Emulsifying agent
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
Edetic acid E00094 6049 Antimicrobial preservative; Complexing agent
Ethyl acetate E00192 8857 Flavoring agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monooleate E00473 5283468 Bioadhesive material; Emollient; Emulsifying agent; Emulsion stabilizing agent; Gelling agent; Modified-release agent; Surfactant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Saccharin sodium dihydrate E00577 46942257 Flavoring agent
Silotermo carmine G E00611 135487652 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Aluminum trihydroxide E00505 10176082 Alkalizing agent; Vaccine adjuvant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium phosphate E00298 24456 Anticaking agent; Buffering agent; Desiccant; Diluent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose anhydrous E00394 107526 Binding agent; Diluent; Flavoring agent; Tonicity agent
Dextrose monohydrate E00538 22814120 Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd E00585 56841934 Colorant
Elemental iron E00280 23925 Other agent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lithol rubin BCA E00607 135423095 Colorant
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbitan monolaurate E00508 11046239 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Zinc stearate E00209 11178 lubricant
⏷ Show the Full List of 76 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Aspirin 81 mg tablet 81 mg Oral Tablet Oral
Aspirin 81 mg tablet 81 mg Delayed Release Oral Tablet Oral
Aspirin 325 mg tablet 325 mg Delayed Release Oral Tablet Oral
Aspirin 325 mg tablet 325 mg Enteric Coated Tablet Oral
Aspirin 81 mg tablet 81 mg Enteric Coated Tablet Oral
Aspirin 81 mg tablet 81 mg Delayed Release Tablet Oral
Aspirin 500 mg tablet 500 mg Oral Tablet Oral
Aspirin 300 mg tablet 300 mg Chewable Tablet Oral
Aspirin 60 mg tablet 60 mg Chewable Tablet Oral
Aspirin 81 mg tablet 81 mg Disintegrating Oral Tablet Oral
Aspirin 81 mg tablet 81 mg Chewable Tablet Oral
Aspirin 325 mg tablet 325 mg Oral Tablet Oral
Aspirin 162.5 mg capsule 162.5 mg 24 HR Extended Release Oral Capsule Oral
Aspirin 120 mg tablet 120 mg Chewable Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Aspirin FDA Label
2 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139).
4 Protective Effect of Aspirin on COVID-19 Patients (PEAC)
5 BDDCS applied to over 900 drugs
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
9 CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998 Dec;8(6):529-41. doi: 10.1097/00008571-199812000-00010.
10 Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry. 2012 Jul 3;2(7):e129. doi: 10.1038/tp.2012.57.
11 ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct;139(4):1190-7. doi: 10.1053/j.gastro.2010.06.071. Epub 2010 Jul 14.
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13 Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007 Jun;64(6):689-97. doi: 10.1001/archpsyc.64.6.689.
14 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
15 A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010 Aug;42(8):711-4. doi: 10.1038/ng.632. Epub 2010 Jul 18.
16 HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
17 Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007 Oct;164(10):1530-8. doi: 10.1176/appi.ajp.2007.06122018.
18 The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
19 Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
20 A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
21 Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
22 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
23 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
24 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
25 Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
26 Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
27 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
28 Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol. 2008 Nov;74(5):1399-406. doi: 10.1124/mol.108.049569. Epub 2008 Aug 4.
29 Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
30 DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
31 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
32 Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
33 Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
34 Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
35 Grennan DM, Ferry DG, Ashworth ME, Kenny RE, Mackinnnon M "The aspirin-ibuprofen interaction in rheumatoid arthritis." Br J Clin Pharmacol 8 (1979): 497-503. [PMID: 389264]
36 Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]
37 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
38 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
39 Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
40 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
41 Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
42 Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
43 Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
44 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
45 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
46 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
47 Barrow MV, Quick DT, Cunningham RW "Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases." Arch Intern Med 120 (1967): 620-4. [PMID: 6054600]
48 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49 Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
50 Product Information. Lovenox (enoxaparin). Rhone-Poulenc Rorer, Collegeville, PA.
51 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
52 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
53 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
54 Product Information. Cerebyx (fosphenytoin). Parke-Davis, Morris Plains, NJ.
55 Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
56 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
57 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
58 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
59 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
60 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
62 Cerner Multum, Inc. "Australian Product Information.".
63 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
64 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
65 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
66 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]